Skip to main content
Premium Trial:

Request an Annual Quote

DHMRI Buys Immune Tolerance Institute

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The David H. Murdock Research Institute today announced it has acquired the Immune Tolerance Institute for an undisclosed amount.

The acquisition enhances DHMRI's capabilities to discover novel immunomodulatory therapies and corresponding biomarkers for translation into clinical practice, DHMRI said.

"The acquisition of ITI will allow us to extend the DMHRI's capabilities even further into the pre-clinical and clinical settings, and thus provide increasingly integrated solutions from discovery into development, ultimately improving the health of patients and consumers alike," DMHRI President Mike Luther said in a statement.

Based in Kannapolis, NC, DHMRI provides genomic, proteomic, cellular, and bioinformatics technology platforms to academic and industry partners. ITI is a non-profit based in Menlo Park, Calif., and develops treatments for immune system-related diseases.

Last year, DHMRI and ITI established a research center to speed up discovery and development of treatments for such conditions.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.